semaglutide for thyroid patients does affect function Hashimoto's and GLP-1: what thyroid need to know before starting Semaglutide Thyroid Cancer Warning: What

In the PIONEER 3 trial, oral semaglutide (7 mg and 14 mg/day) showed a significant decrease in HbA1c compared to the DPP-4 inhibitor sitagliptin (100 mg/day) in patients with T2DM inadequately responsive to metformin, while at the same time promoting a significant decrease in body weight [15]

Clarifying treatment goals with your healthcare provider ensures that progress is measured appropriately and that expectations align with clinical evidence

A medication review is the first step for anyone who's recently started new prescriptions

While literature on GLP-1 RAs and PETD is currently limited, the mechanism is well established as reports of PETD after rapid weight loss, especially in bariatric surgery, are well known

Animal and human studies have shown that GLP-1 receptor agonists may enhance neuroplasticity and protect dopamine-producing neurons, supporting both migraine reduction and cognitive function

Most adverse effects rose sharply at lower doses and plateaued at higher doses